Market Cap: $293.13B
Market Cap: $293.13B
Open
$157.19
Prev. Close
$159.13
High
$157.48
Low
$154.15
Novartis AG researches, develops, manufactures, distributes, markets, and sells pharmaceutical medicines in Switzerland and internationally. The company offers Entresto, an angiotensin receptorneprilysin inhibitor to treat symptomatic chronic heart failure with reduced ejection fraction (HFrEF); Cosentyx to treat plaque psoriasis, pso riatic arthritis, ankylosing spondylitis, and nonradiographic axial spondy loarthritis; Kisqali, a selective oral cyclin dependent inhibitor of kinases 4 and 6 (CDK4/6); Promacta/Revolade to treat immune thrombocytopenia (ITP), thrombocytopenia, and patients with severe aplastic anemia (SAA); Tafinlar+Mekinist, an oral combination therapy to treat patients with certain types of cancers; and Jakavi for the treatment of myelofibrosis, polycythemia vera, and acute or chronic graftversushost disease (GvHD).
Novartis AG trades on the New York Stock Exchange under the ticker NVS, priced in USD.
Novartis AG has a market capitalisation of $293.13B, based on its latest share price.
NVS trades at 30.76 times its trailing 12-month earnings.
Over the past 52 weeks NVS has traded between $123.24 and $170.46.
Yes. Novartis AG's dividend yields 2.76% at the current share price, paying out 90% of its earnings.
Highly profitable: keeps 18.1% of revenue as net profit.
The analyst consensus rating for NVS is Hold. Analysts' average 12-month price target of $146.67 implies 6% downside.
Vasant Narasimhan is the CEO of Novartis AG, which is headquartered in Basel.
Generated automatically from reported financial data. General information only, not financial advice.

Novartis AG ( NVS ) continues to establish itself as a leader in the pharmaceutical industry, particularly as it navigates the challenges and opportunities surrounding patent expirations and changing…

Novartis AG (Ticker: NVS) continues to position itself as a key player in the fight against Facioscapulohumeral Muscular Dystrophy (FSHD), a debilitating genetic condition that affects tens of thousan…
Novartis Drives Forward with Strategic Acquisition for Allergy Treatments Swiss pharmaceutical giant Novartis is poised to enhance its portfolio in allergy treatments through the acquisition of U.S.-b…
Novartis Expands Reach with FDA Approval of Cosentyx for Pediatric Use In a significant development for pediatric care in autoimmune disorders, Novartis AG secures U.S. Food and Drug Administration (F…